{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:44:19Z","timestamp":1792269859776,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"DOI":"10.1007\/s10585-026-10436-8","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:05:24Z","timestamp":1792224324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Surgical resection versus stereotactic body radiotherapy for oligometastatic breast cancer to the liver"],"prefix":"10.1007","volume":"43","author":[{"given":"Lianjie","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongtao","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qigen","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"key":"10436_CR1","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s11684-024-1058-6","volume":"18","author":"Q Li","year":"2024","unstructured":"Li Q, Xia C, Li H, Yan X, Yang F, Cao M, Zhang S, Teng Y, He S, Cao M, Chen W (2024) Disparities in 36 cancers across 185 countries: secondary analysis of global cancer statistics. Front Med 18:911\u2013920","journal-title":"Front Med"},{"key":"10436_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, Cardoso MJ, Carey LA, Dawood S, Del Mastro L, Denkert C, Fallenberg EM, Francis PA, Gamal-Eldin H, Gelmon K, Geyer CE, Gnant M, Guarneri V, Gupta S, Kim SB, Krug D, Martin M, Meattini I, Morrow M, Janni W, Paluch-Shimon S, Partridge A, Poortmans P, Pusztai L, Regan MM, Sparano J, Spanic T, Swain S, Tjulandin S, Toi M, Trapani D, Tutt A, Xu B, Curigliano G, Harbeck N (2024) ESMO guidelines committee. electronic address: clinicalguidelines@esmo.org. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 35:159\u2013182","journal-title":"Ann Oncol"},{"key":"10436_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcancer.2019.08.012","volume":"60","author":"Y Liang","year":"2020","unstructured":"Liang Y, Zhang H, Song X, Yang Q (2020) Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets. Semin Cancer Biol 60:14\u201327","journal-title":"Semin Cancer Biol"},{"key":"10436_CR4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1186\/s12885-019-6311-z","volume":"19","author":"R Wang","year":"2019","unstructured":"Wang R, Zhu Y, Liu X, Liao X, He J, Niu L (2019) The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer 19:1091","journal-title":"BMC Cancer"},{"key":"10436_CR5","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1007\/s11864-024-01275-4","volume":"25","author":"DN Zouki","year":"2024","unstructured":"Zouki DN, Karatrasoglou EA, Pilichos G, Papadimitraki E (2024) Oligometastatic breast cancer: seeking the cure by redefining stage IV disease? Curr Treat Options Oncol 25:1482\u20131494","journal-title":"Curr Treat Options Oncol"},{"key":"10436_CR6","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1111\/1759-7714.15073","volume":"14","author":"Y Chai","year":"2023","unstructured":"Chai Y, Chen Y, Liu J, He M, Jiang M, Xu B, Li Q (2023) Improved survival in patients with isolated liver metastasis at initial diagnosis with surgery at primary and metastatic sites: A population-based study in patients with breast cancer. Thorac Cancer 14:2793\u20132803","journal-title":"Thorac Cancer"},{"key":"10436_CR7","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ijrobp.2024.10.030","volume":"121","author":"JP Reddy","year":"2025","unstructured":"Reddy JP, Sherry AD, Fellman B et al (2025) Adding metastasis-directed therapy to standard-of-care systemic therapy for oligometastatic breast cancer (EXTEND): a multicenter, randomized phase 2 trial. Int J Radiat Oncol Biol Phys 121:885\u2013893. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.10.030","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10436_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"CJ Tsai","year":"2024","unstructured":"Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, Guttmann D, Yeh R, Gelblum DY, Namakydoust A, Preeshagul I, Modi S, Seidman A, Traina T, Drullinsky P, Flynn J, Zhang Z, Rimner A, Gillespie EF, Gomez DR, Lee NY, Berger M, Robson ME, Reis-Filho JS, Riaz N, Rudin CM, Powell SN, CURB Study Group (2024) Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet 403:171\u2013182","journal-title":"Lancet"},{"key":"10436_CR9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.29271\/jcpsp.2024.05.604","volume":"34","author":"E Sen","year":"2024","unstructured":"Sen E, Canbak T, Bostanci O, Battal M (2024) Outcome and factors related to isolated liver metastasis due to breast cancer. J Coll Physicians Surg Pak 34:604\u2013609","journal-title":"J Coll Physicians Surg Pak"},{"key":"10436_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s12672-024-01595-9","volume":"15","author":"X Li","year":"2024","unstructured":"Li X, Sun Y, Tang L, Li Y, Yang X (2024) Treatment of metastatic breast cancer by stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS). Discov Oncol 15:733","journal-title":"Discov Oncol"},{"key":"10436_CR11","doi-asserted-by":"publisher","first-page":"e2300275","DOI":"10.1200\/GO.23.00275","volume":"10","author":"N Salim","year":"2024","unstructured":"Salim N, Tumanova K, Popodko A, Libson E (2024) Second chance for cure: stereotactic ablative radiotherapy in oligometastatic disease. JCO Glob Oncol 10:e2300275","journal-title":"JCO Glob Oncol"},{"key":"10436_CR12","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1001\/jamaoncol.2022.4394","volume":"8","author":"R Olson","year":"2022","unstructured":"Olson R, Jiang W, Liu M, Bergman A, Schellenberg D, Mou B, Alexander A, Carolan H, Hsu F, Miller S, Atrchian S, Chan E, Ho C, Mohamed I, Lin A, Berrang T, Bang A, Chng N, Matthews Q, Baker S, Huang V, Mestrovic A, Hyde D, Lund C, Pai H, Valev B, Lefresene S, Tyldesley S (2022) Treatment with stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer: primary toxic effect results of the nonrandomized phase 2 SABR-5 clinical trial. JAMA Oncol 8:1644\u20131650","journal-title":"JAMA Oncol"},{"key":"10436_CR13","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB et al (2020) Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 21:e18\u2013e28. https:\/\/doi.org\/10.1016\/S1470-2045(19)30718-1","journal-title":"Lancet Oncol"},{"key":"10436_CR14","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Published November 27 (2017) https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf"},{"key":"10436_CR15","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1097\/JS9.0000000000000711","volume":"109","author":"LiverGroup.org Collaborative","year":"2023","unstructured":"LiverGroup.org Collaborative (2023) Outcomes of elective liver surgery worldwide: a global, prospective, multicenter, cross-sectional study. Int J Surg 109:3954\u20133966","journal-title":"Int J Surg"},{"key":"10436_CR16","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s10147-025-02776-4","volume":"30","author":"N Imano","year":"2025","unstructured":"Imano N (2025) Stereotactic body radiotherapy for oligometastatic disease: current evidence and future perspectives. Int J Clin Oncol 30:1505\u20131521","journal-title":"Int J Clin Oncol"},{"key":"10436_CR17","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1159\/000486523","volume":"35","author":"G Ercolani","year":"2018","unstructured":"Ercolani G, Zanello M, Serenari M, Cescon M, Cucchetti A, Ravaioli M, Del Gaudio M, D\u2019Errico A, Brandi G, Pinna AD (2018) Ten-year survival after liver resection for breast metastases: a single-center experience. Dig Surg 35:372\u2013380","journal-title":"Dig Surg"},{"key":"10436_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3390\/jpm11030187","volume":"11","author":"A Orlandi","year":"2021","unstructured":"Orlandi A, Pontolillo L, Mele C, Pasqualoni M, Pannunzio S, Cannizzaro MC, Cutigni C, Palazzo A, Garufi G, Vellone M, Ardito F, Franceschini G, Sanchez AM, Cassano A, Giuliante F, Bria E, Tortora G (2021) Liver metastasectomy for metastatic breast cancer patients: a single institution retrospective analysis. J Pers Med 11:187","journal-title":"J Pers Med"},{"key":"10436_CR19","first-page":"688","volume":"62","author":"T Ye","year":"2015","unstructured":"Ye T, Yang B, Tong H, Zhang Y, Xia J (2015) Long-term outcomes of surgical resection for liver metastasis from breast cancer. Hepatogastroenterology 62:688\u2013692","journal-title":"Hepatogastroenterology"},{"key":"10436_CR20","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.21873\/invivo.11372","volume":"32","author":"N Bacalbasa","year":"2018","unstructured":"Bacalbasa N, Balescu I, Ilie V, Florea R, Sorop A, Brasoveanu V, Brezean I, Vilcu M, Dima S, Popescu I (2018) The impact on the long-term outcomes of hormonal status after hepatic resection for breast cancer liver metastases. Vivo 32:1247\u20131253","journal-title":"Vivo"},{"key":"10436_CR21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12885-018-4191-2","volume":"18","author":"N Andratschke","year":"2018","unstructured":"Andratschke N, Alheid H, Allg\u00e4uer M, Becker G, Blanck O, Boda-Heggemann J, Brunner T, Duma M, Gerum S, Guckenberger M, Hildebrandt G, Klement RJ, Lewitzki V, Ostheimer C, Papachristofilou A, Petersen C, Schneider T, Semrau R, Wachter S, Habermehl D (2018) The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer 18:283","journal-title":"BMC Cancer"},{"key":"10436_CR22","doi-asserted-by":"publisher","first-page":"e31834","DOI":"10.1002\/pbc.31834","volume":"72","author":"S Reddy","year":"2025","unstructured":"Reddy S, Upadhyay R, Klamer B, Singh R, Konieczkowski D, Cripe T, Yeager ND, Roberts RD, Aldrink JH, Setty B, Scharschmidt T, Palmer J, Baliga S (2025) Local control and toxicity outcomes after stereotactic body radiation therapy for metastatic osteosarcoma in pediatric patients. Pediatr Blood Cancer 72:e31834","journal-title":"Pediatr Blood Cancer"},{"key":"10436_CR23","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3390\/cancers17020296","volume":"17","author":"S Dirkx","year":"2025","unstructured":"Dirkx S, Van Laere S, Gevaert T, De Ridder M (2025) Precision in motion management: long-term local control and prognostic insights in SBRT for oligometastatic lung and liver metastases. Cancers (Basel) 17:296","journal-title":"Cancers (Basel)"},{"key":"10436_CR24","first-page":"100947","volume":"52","author":"CS Dejonckheere","year":"2025","unstructured":"Dejonckheere CS, Bilski M, Nour Y, Scafa D, Cisek P, Korab K, Ponikowska J, Wojtyna E, Sroka S, Kugel F, Grimmer M, Holz J, Garbe S, Eich P, Gkika E (2025) Renato Sarria G, Philipp Layer J. A dosimetric comparison of different radiotherapy modalities for Non-Resected oligometastatic liver Disease. Clin Transl Radiat Oncol 52:100947","journal-title":"Clin Transl Radiat Oncol"},{"key":"10436_CR25","doi-asserted-by":"publisher","first-page":"111280","DOI":"10.1016\/j.radonc.2025.111280","volume":"214","author":"M Bilski","year":"2026","unstructured":"Bilski M, Kuncman \u0141, Orzechowska M, Cisek P, Mastroleo F, Skrzypczak M, Sroka S, Wojtyna E, Ferentinos K, Hering K, Fijuth J, Jereczek-Fossa BA, Ha HM, Medenwald D, Fabritius MP, Corradini S, Seidensticker M, Ricke J, Pech M, Fuchs F, Rogowski P (2026) Survival outcomes and toxicity profile after CT-guided HDR brachytherapy (interventional radiotherapy) for liver oligometastases in breast cancer patients: The BRALIBREST real world multicenter study. Radiother Oncol 214:111280","journal-title":"Radiother Oncol"},{"key":"10436_CR26","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17:425\u2013439","journal-title":"Lancet Oncol"},{"key":"10436_CR27","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1159\/000503847","volume":"15","author":"C Cha","year":"2020","unstructured":"Cha C, Ahn SG, Yoo TK, Kim KM, Bae SJ, Yoon C, Park S, Sohn J, Jeong J (2020) Local treatment in addition to endocrine therapy in hormone receptor-positive and HER2-negative oligometastatic breast cancer patients: a retrospective multicenter analysis. Breast Care (Basel) 15:408\u2013414","journal-title":"Breast Care (Basel)"},{"key":"10436_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s12032-022-01788-8","volume":"39","author":"P Pacifico","year":"2022","unstructured":"Pacifico P, Colciago RR, De Felice F, Boldrini L, Salvestrini V, Nardone V, Desideri I, Greco C, Arcangeli S (2022) A critical review on oligometastatic disease: a radiation oncologist\u2019s perspective. Med Oncol 39:181","journal-title":"Med Oncol"},{"key":"10436_CR29","doi-asserted-by":"publisher","first-page":"103839","DOI":"10.1016\/j.breast.2024.103839","volume":"79","author":"RR Colciago","year":"2025","unstructured":"Colciago RR, De Santis MC, Giandini C, Carnevale MG, Di Cosimo S (2025) Treatment of oligometastatic breast cancer: the role of patient selection. Breast 79:103839","journal-title":"Breast"},{"key":"10436_CR30","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.3390\/cancers17142406","volume":"17","author":"T Shien","year":"2025","unstructured":"Shien T, Nakamoto S, Fujiwara Y, Kosaka M, Narahara Y, Fujii K, Maeda R, Kato S, Mimata A, Yoshioka R, Kuwahara C, Tsukioki T, Takahashi Y, Iwatani T, Tanioka M (2025) Definitions of, advances in, and treatment strategies for breast cancer oligometastasis. Cancers (Basel) 17:2406","journal-title":"Cancers (Basel)"},{"key":"10436_CR31","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1007\/s00345-018-2609-8","volume":"37","author":"B Dhondt","year":"2019","unstructured":"Dhondt B, De Bleser E, Claeys T, Buelens S, Lumen N, Vandesompele J, Beckers A, Fonteyne V, Van der Eecken K, De Bruycker A, Paul J, Gramme P, Ost P (2019) Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time. World J Urol 37:2557\u20132564","journal-title":"World J Urol"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-026-10436-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-026-10436-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-026-10436-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:03:20Z","timestamp":1792267400000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-026-10436-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10436"],"URL":"https:\/\/doi.org\/10.1007\/s10585-026-10436-8","relation":{},"ISSN":["1573-7276"],"issn-type":[{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Research Committee of Henan Cancer Hospital, the First Affiliated Hospital of Zhengzhou University, and The Second Affiliated Hospital of Zhengzhou University, and written informed consent was obtained from all patients prior to initial treatment. All methods were performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"55"}}